Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Мукополисахаридоз тип I

Список литературы

  1. Klein D. A., Paradise S. L., Reeder R. M. Amenorrhea: A Systematic Approach to Diagnosis and Management //American Family Physician. – 2019. – Т. 100. – №. 1.
  2. Hickey M., Balen A. Menstrual disorders in adolescence: investigation and management //Human reproduction update. – 2003. – Т. 9. – №. 5. – С. 493-504.
  3. Munro M. G. et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions //International Journal of Gynecology & Obstetrics. – 2018.
  4. Michelle Wellman. Investigating primary and secondary amenorrhoea. Clinical investigations from the RACP.
  5. ACOG. Committee Opinion No. 651: Menstruation in girls and adolescents: using the menstrual cycle as a vital sign //Obstet Gynecol. – 2015. – Т. 126.
  6. Widholm O., Kantero R. L. A statistical analysis of the menstrual patterns of 8,000 Finnish girls and their mothers //Acta obstetricia et gynecologica Scandinavica. Supplement. – 1971. – Т. 14.
  7. World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. II. Longitudinal study of menstrual patterns in the early postmenarcheal period, duration of bleeding episodes and menstrual cycles. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health Care. 1986 Jul;7(4):236-44.
  8. ACOG Polycystic Ovary Syndrome,” Obstetrics & Gynecology, vol. 131, no. 6, pp. e157– e171, Jun. 2018, doi: 10.1097/AOG.0000000000002656.
  9. Gordon C. M. et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline //The Journal of Clinical Endocrinology & Metabolism. – 2017. – Т. 102. – №. 5. – С. 1413-1439.
  10. Boeh U. et al. European consensus statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment //Nature Reviews Endocrinology. – 2015. – Т. 9. – №. 11. – С. 547-564.
  11. Уварова Е. В., Трифонова Е. В. Гипогонадотропный гипогонадизм (обзор литературы) //Педиатрическая фармакология. – 2008. – Т. 5. – №. 4.
  12. Мельниченко Г. А. и др. Федеральные клинические рекомендации по гиперпролактинемии: клиника, диагностика, дифференциальная диагностика и методы лечения //Проблемы эндокринологии. – 2013. – Т. 59. – №. 6.
  13. Nelson L. M. Primary ovarian insufficiency //New England Journal of Medicine. – 2009. – Т. 360. – №. 6. – С. 606-614.
  14. Klein D. A. et al. Disorders of Puberty: An Approach to Diagnosis and Management //American family physician. – 2017. – Т. 96. – №. 9.
  15. Practice Committee of the American Society for Reproductive Medicine et al. Current evaluation of amenorrhea //Fertility and sterility. – 2004. – Т. 82. – С. 33-39.
  16. Адамян Л. В., Кулаков В. И., Хашукоева А. З. Пороки развития матки и влагалища // М.: Медицина. – 1998. – Т. 327. – С. 1., Медицина. Москва.
  17. Bang R. A. et al. High prevalence of gynaecological diseases in rural Indian women //The lancet. – 1989. – Т. 333. – №. 8629. – С. 85-88.
  18. Jeyaseelan L., Rao P. S. S. Effect of occupation on menstrual cycle length: causal model //Human biology. – 1995. – С. 283-290.
  19. Bhatia J. C. et al. Levels and determinants of gynecological morbidity in a district of south India //Studies in family planning. – 1997. – Т. 28. – №. 2. – С. 95-104.
  20. Filippi V. et al. Asking questions about women’s reproductive health: validity and reliability of survey findings from Istanbul //Tropical Medicine & International Health. – 1997. – Т. 2. – №. 1. – С. 47-56.
  21. Bulut A. et al. Contraceptive choice and reproductive morbidity in Istanbul //Studies in family planning. – 1997. – С. 35-43.
  22. Hernandez I. et al. Prevalence and etiology of secondary amenorrhea in a selected Mexican population //Ginecologia y obstetricia de Mexico. – 1999. – Т. 67. – С. 374-376.
  23. Harlow S. D., Campbell O. M. R. Epidemiology of menstrual disorders in developing countries: a systematic review //BJOG: An International Journal of Obstetrics & Gynaecology: REVIEW. – 2004. – Т. 111. – №. 1. – С. 6-16.
  24. Nuñez Troconis J. T. Trastornos menstruales en estudiantes universitarias: II Menarquia y dismenorrea //Rev Obstet Ginecol Venez. – 1991. – Т. 51. – №. 2. – С. 105-8.
  25. Nuñez Troconis J., Girón Páez H., Nuñez Virla L. Alteraciones del ciclo menstrual en internas y residentes //Rev Obstet Ginecol Venez. – 1999. – Т. 59. – №. 4. – С. 257-62.
  26. INSLER V. et al. Functional classification of patients selected for gonadotropic therapy //Obstetrics & Gynecology. – 1968. – Т. 32. – №. 5. – С. 620-626.
  27. C. G. E. Chernukha, B. A. E. Bobrov, G. D. V. Gusev, T. G. I. Tabeeva, N. T. E. Nikitina T, and A. I. N. Agamamedova, “Psychopathological features and endocrine and metabolic profile in patients with functional hypothalamic amenorrhea,” Akush. Ginekol. (Sofiia)., vol. 2_2019, pp. 105–112, Mar. 2019, doi: 10.18565/aig.2019.2.105-112.
  28. De Lange W. E. et al. Primary amenorrhoea with hypertension due to 17‐Hydroxylase deficiency: Therapy with Dexamethasone and Ethinyloestradiol //Acta Medica Scandinavica. – 1973. – Т. 193. – №. 1‐6. – С. 565-571.
  29. Клинические рекомендации «Синдром поликитозных яичников». 2016.
  30. Klein D. A., Poth M. A. Amenorrhea: an approach to diagnosis and management //Am Fam Physician. – 2013. – Т. 87. – №. 11. – С. 781-788.
  31. Herman-Giddens M. E. et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network //Pediatrics. – 1997. – Т. 99. – №. 4. – С. 505-512.
  32. Melmed S. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline //The Journal of Clinical Endocrinology & Metabolism. – 2011. – Т. 96. – №. 2. – С. 273-288.
  33. Molitch M. E. Diagnosis and treatment of pituitary adenomas: a review //Jama. – 2017. – Т. 317. – №. 5. – С. 516-524.
  34. Martin K. A. et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline //The Journal of Clinical Endocrinology & Metabolism. – 2018. – Т. 103. – №. 4. – С. 1233-1257.
  35. Myers E. M., Hurst B. S. Comprehensive management of severe Asherman syndrome and amenorrhea //Fertility and sterility. – 2012. – Т. 97. – №. 1. – С. 160-164.
  36. ACOG Committee Opinion No. 728:Müllerian agenesis: diagnosis, management, and treatment., Obstetrics & Gynecology, vol. 131, no. 1, pp. e35–e42, Jan. 2018, doi: 10.1097/AOG.0000000000002458.
  37. Practice Committee of the American Society for Reproductive Medicine et al. Current evaluation of amenorrhea //Fertility and sterility. - 2008. - Vol. 90 (suppl 3). - p. 219-225.
  38. Rebar R. W., Connolly H. V. Clinical features of young women with hypergonadotropic amenorrhea //Fertility and sterility. – 1990. – Т. 53. – №. 5. – С. 804-810.
  39. American College of Obstetricians and Gynecologists et al. Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women //Obstet Gynecol. – 2014. – Т. 124. – №. 1. – С. 193-197.
  40. ESHRE Guideline Group on POI et al. ESHRE Guideline: management of women with premature ovarian insufficiency //Human Reproduction. – 2016. – Т. 31. – №. 5. – С. 926-937.
  41. Teede H. J. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome //Human Reproduction. – 2018. – Т. 33. – №. 9. – С. 1602-1618.
  42. Nelson S. M. Biomarkers of ovarian response: current and future applications //Fertility and sterility. – 2013. – Т. 99. – №. 4. – С. 963-969.
  43. Tosi F. et al. Implications of androgen assay accuracy in the phenotyping of women with polycystic ovary syndrome //The Journal of Clinical Endocrinology & Metabolism. – 2016. – Т. 101. – №. 2. – С. 610-618.
  44. Master-Hunter T., Heiman D. L. Amenorrhea: evaluation and treatment //American family physician. – 2006. – Т. 73. – №. 8. – С. 1374-1382.
  45. Найдукова А. А. и др. Значение антимюллерова гормона в диагностике синдрома поликистозных яичников //Акушерство и гинекология. – 2017. – №. 1. – С. 46-52.
  46. Geckinli B. B. et al. Prevalence of X-aneuploidies, X-structural abnormalities and 46, XY sex reversal in Turkish women with primary amenorrhea or premature ovarian insufficiency //European Journal of Obstetrics & Gynecology and Reproductive Biology. – 20.
  47. De Souza MJ, Nattiv A, Joy E, Misra M, Williams NI, Mallinson RJ, Gibbs JC, Olmsted M, Goolsby M, Matheson G; Expert Panel. 2014 Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad: 1st International Conference held in San Francisco, California, May 2012 and 2nd International Conference held in Indianapolis, Indiana, May 2013. Br J Sports Med. 2014 Feb;48(4):289
  48. Crabtree N. J. et al. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions //Journal of Clinical Densitometry. – 2014. – Т. 17. – №. 2. – С. 225-242.
  49. M. A. C. of S. M. Nattiv, A, Loucks, AB, Manore, MM, Sanborn, CF, Sundgot-Borgen, J, Warren, American College of Sports Medicine position stand. The female athlete triad., vol. 39, no. 10. 2007.
  50. Battino, S., Ben-Ami, M., Geslevich, Y., Weiner, E., & Shalev, E. (1996). Factors Associated with Withdrawal Bleeding after Administration of Oral Dydrogesterone or Medroxyprogesterone Acetate in Women with Secondary Amenorrhea. Gynecologic and Obstetric .
  51. Уварова Е. В. и др. Показания и особенности использования гестагена дидрогестерона в пубертатном периоде //Репродуктивное здоровье детей и подростков. – 2014. – №. 2 (55).
  52. Panay, N., Pritsch, M., & Alt, J. (2007). Cyclical dydrogesterone in secondary amenorrhea: Results of a double-blind, placebo-controlled, randomized study. Gynecological Endocrinology, 23(11), 611–618.
  53. Papadakis, G. E., Xu, C., & Pitteloud, N. (2020). Hypothalamic Disorders During Ovulation, Pregnancy, and Lactation. Maternal-Fetal and Neonatal Endocrinology, 217–240.
  54. Mountjoy M. et al. The IOC consensus statement: beyond the female athlete triad—Relative Energy Deficiency in Sport (RED-S) //Br J Sports Med. – 2014. – Т. 48. – №. 7. – С. 491-497.
  55. Jagielska G. et al. Bone mineral density in adolescent girls with anorexia nervosa //European child & adolescent psychiatry. – 2002. – Т. 11. – №. 2. – С. 57-62.
  56. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991 Feb;72(2):374-81.
  57. Cardim H. J. P. et al. The insulin-like growth factor-I system and hormone replacement therapy //Fertility and sterility. – 2001. – Т. 75. – №. 2. – С. 282-287.
  58. Kam G. Y. W. et al. Estrogens exert route-and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex //The Journal of Clinical Endocrinology & Metabolism. – 2000. – Т. 85. – №. 5.
  59. Megi Resulaj, Sai Polineni, Erinne Meenaghan, Kamryn Eddy, Hang Lee, Pouneh K Fazeli Transdermal Estrogen in Women With Anorexia Nervosa: An Exploratory Pilot Study. JBMR Plus. 2020 Jan; 4(1): e10251.
  60. Nassiri, F., Cusimano, M. D. Prolactinomas: diagnosis and treatment. Expert Review of Endocrinology & Metabolism, 7(2), 233–241.
  61. Сохадзе Х.С., Сабуров А.В., Гаврилова Н.П. Реализация программы вспомогательных репродуктивных технологий у женщин с гиперпролактинемией и дисфункцией щитовидной железы // Фундаментальные исследования. – 2013. – № 9-4. – С. 734-743.
  62. Мельниченко Г.А., Дзеранова Л.К., Бармина И.И., Кадашев Б.А., Астафьева Л.И., Шишкина Л.В. Резистентность к терапии агонистами дофамина у пациентов с гиперпролактинемией. Вестник репродуктивного здоровья. 2007;(1):33-41.
  63. Verhelst J. et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients //The Journal of Clinical Endocrinology & Metabolism. – 1999. – Т. 84. – № . 7. – С. 2518-2522.
  64. De Rosa M. et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence //The Journal of Clinical Endocrinology & Metabolism. – 2004. – Т. 89. – №. 2.
  65. Colao A. et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24- month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis //The Journal of Clinical Endocrinology & Metabolism. – 2004.
  66. De Rosa M. et al. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males //Clinical endocrinology. – 2006. – Т. 64. – №. 3. – С. 307-313.
  67. Di Sarno A. et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy //The Journal of Clinical Endocrinology & Metabolism. – 2001. – Т. 86. – №. 11. – С. 5256-5261.
  68. Ono M. et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients //The Journal of Clinical Endocrinology & Metabolism. – 2008. – Т. 93. – №. 12. – С. 4721-4727.
  69. Pascal-Vigneron V. et al. Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study //Presse medicale (Paris, France: 1983). – 1995. – Т. 24. – №. 16. – С. 753-757.
  70. Дзеранова Л. К., Иловайская И. А. Диагностика и лечение гиперпролактинемии: клинические рекомендации Международного эндокринологического общества и взгляд российских экспертов //Эффективная фармакотерапия. – 2012. – №. 18. – С. 28-33.
  71. Gravholt C. H. et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting //European journal of endocrinology. – 2017. – Т. 177. – №. 3. – С. G1-G70.
  72. Gomez-Lobo V, Oelschlager AA; North American Society for Pediatric and Adolescent Gynecology. Gynecological challenges in the diagnosis and care of patients with DSD: The role of the obstetrician gynecologist in the multidisciplinary approach to the patient. Am J Med Genet C Semin Med Genet. 2017 Jun;175(2):300-303.
  73. Klein, K. O., Rosenfield, R. L., Santen, R. J., Gawlik, A. M., Backeljauw. Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1790–1803.
  74. Crofton P. M. et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover //Clinical endocrinology. – 2010. – Т. 73. – №. 6. – С. 707-714.
  75. Legro R. S. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline //The Journal of Clinical Endocrinology & Metabolism. – 2013. – Т. 98. – №. 12. – С. 4565-4592.
  76. К. Д. Кулаков, В.И., Адамян, Л.В., Мурватов, “Способ брюшинного кольпопоэза.”
  77. “Адамян, Л.В., Бобкова М.В., Д.А. Сипченко. Усовершенствованная методика операции кольпопоэза из тазовой брюшины с лапароскопической ассистенцией. RU 2587723 C1.”
  78. А. С. Бобкова, М.В., Адамян, Л.В., Аракелян, “Новый способ операции брюшинного кольпопоэза, выполняемого для хирургической коррекции порока развития внутренних половых органов - аплазии влагалища и матки. RU 2 585 739 C9.”
  79. Walch K. et al. Functional and anatomic results after creation of a neovagina according to Wharton-Sheares-George in patients with Mayer-Rokitansky-Küster-Hauser syndrome—long- term follow-up //Fertility and sterility. – 2011. – Т. 96. – №. 2. – С. 492-497.
  80. Hughes I. A. et al. Consensus statement on management of intersex disorders //Journal of pediatric urology. – 2006. – Т. 2. – №. 3. – С. 148-162.
  81. Lee, K., Hong, J., Jung, H., Jeong, H., Moon, S., Park, W., … Shin, J. (2019). Imperforate Hymen: A Comprehensive Systematic Review. Journal of Clinical Medicine, 8(1), 56. doi:10.3390/jcm8010056.
  82. Conforti A. et al. The management of Asherman syndrome: a review of literature //Reproductive Biology and Endocrinology. – 2013. – Т. 11. – №. 1. – С. 118.
  83. Johary, J., Xue, M., Zhu, X., Xu, D., & Velu, P. P. (2014). Efficacy of Estrogen Therapy in Patients With Intrauterine Adhesions: Systematic Review. Journal of Minimally Invasive Gynecology, 21(1), 44–54.
  84. Worldwide A. A. M. I. G. AAGL practice report: practice guidelines for management of intrauterine synechiae //Journal of Minimally Invasive Gynecology. – 2010. – Т. 17. – №. 1. – С. 1- 7.
  85. Zhu, R., Duan, H., Gan, L., & Wang, S. (2018). Comparison of Intrauterine Suitable Balloon and Foley Balloon in the Prevention of Adhesion after Hysteroscopic Adhesiolysis. BioMed Research International, 2018.
  86. Liu L, Huang X, Xia E, et al. A cohort study comparing 4 mg and 10 mg daily doses of postoperative oestradiol therapy to prevent adhesion reformation after hysteroscopic adhesiolysis. Hum Fertil (Camb) 2019;22:191–7.
  87. Федеральные клинические рекомендации (протокол лечения) “Женское бесплодие (современные подходы к диагностике и лечению)”. 2019.
  88. Shoham Z. et al. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double‐blind, placebo‐controlled, proof‐of‐ efficacy study //Clinical endocrinology. – 2008. – Т. 69. – №. 3.
  89. Silveira L. F. G., Latronico A. C. Approach to the patient with hypogonadotropic hypogonadism //The Journal of Clinical Endocrinology & Metabolism. – 2013. – Т. 98. – №. 5. – С. 1781-1788.
  90. Abel B. S. et al. Responsiveness to a physiological regimen of GnRH therapy and relation to genotype in women with isolated hypogonadotropic hypogonadism //The Journal of Clinical Endocrinology & Metabolism. – 2013. – Т. 98. – №. 2. – С. E206-E216.
  91. ESHRE Capri Workshop Group. Nutrition and reproduction in women //Human Reproduction Update. – 2006. – Т. 12. – №. 3. – С. 193-207.
  92. Djurovic M. et al. Gonadotropin response to clomiphene and plasma leptin levels in weight recovered but amenorrhoeic patients with anorexia nervosa //Journal of endocrinological investigation. – 2004. – Т. 27. – №. 6. – С. 523-527.
  93. Borges L. E. et al. New protocol of clomiphene citrate treatment in women with hypothalamic amenorrhea //Gynecological Endocrinology. – 2007. – Т. 23. – №. 6. – С. 343-346.
  94. Bryman I. et al. Pregnancy rate and outcome in Swedish women with Turner syndrome //Fertility and sterility. – 2011. – Т. 95. – №. 8. – С. 2507-2510.
  95. Bernard V. et al. Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome //Human Reproduction. – 2016. – Т. 31. – №. 4. – С. 782-788.
  96. Birkebaek N. H. et al. Fertility and pregnancy outcome in Danish women with Turner syndrome //Clinical genetics. – 2002. – Т. 61. – №. 1. – С. 35-39.
  97. Doğer E. et al. Reproductive and obstetric outcomes in mosaic Turner’s Syndrome: a cross- sectional study and review of the literature //Reproductive Biology and Endocrinology. – 2015. – Т. 13. – №. 1. – С. 59.
  98. Y. Nazik, H., Kumtepe, “Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction for women with polycystic ovarian syndrome.,” HealthMED, no. 6(3), pp. 879–883, 2012.
  99. Atay V. et al. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation //Journal of international medical research. – 2006. – Т. 34. – №. 1. – С. 73-76.
  100. Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial //Journal of human reproductive sciences. – 2012. – Т. 5. – №. 3. – С. 262.
  101. Zeinalzadeh M., Basirat Z., Esmailpour M. Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome //The Journal of reproductive medicine. – 2010. – Т. 55. – №. 1-2. – С. 36-40.
  102. Dehbashi S. et al. Comparison of the effects of letrozole and clomiphene citrate on ovulation and pregnancy rate in patients with polycystic ovary syndrome. – 2009.
  103. Begum M. R. et al. Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome //Fertility and sterility. – 2009. – Т. 92. – №. 3. – С. 853-857.
  104. Bayar Ü. et al. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial //Fertility and sterility. – 2006. – Т. 86. – №. 5. – С. 1447-1451.
  105. Badawy A., Aal I. A., Abulatta M. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial //Fertility and sterility. – 2009. – Т. 92. – №. 3. – С. 849-852.
  106. Roy K. K. et al. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome //Journal of human reproductive sciences. – 2012. – Т. 5. – №. 1. – С. 20.
  107. Friedler S. et al. The reproductive potential of patients with Mayer–Rokitansky–Küster– Hauser syndrome using gestational surrogacy: a systematic review //Reproductive biomedicine online. – 2016. – Т. 32. – №. 1. – С. 54-61.
  108. Hughes, I. A., Davies, J. D., Bunch, T. I., Pasterski, V., Mastroyannopoulou, K., & MacDougall, J. (2012). Androgen insensitivity syndrome. The Lancet, 380(9851), 1419–1428.
  109. Guo E. J. et al. Reproductive outcomes after surgical treatment of asherman syndrome: A systematic review //Best Practice & Research Clinical Obstetrics & Gynaecology. – 2019. – Т. 59. – С. 98-114.
  110. Kodaman P. H., Arici A. Intra-uterine adhesions and fertility outcome: how to optimize success? //Current Opinion in Obstetrics and Gynecology. – 2007. – Т. 19. – №. 3. – С. 207-214.
  111. “Клинические рекомендации по диагностике и коррекции нарушений пищевого статуса. Национальная ассоциация клинического питания.”
  112. Gordon, C. M. (2010). Functional Hypothalamic Amenorrhea. New England Journal of Medicine, 363(4), 365–371.
  113. Evans-Hoeker E. A., Young S. L. Endometrial receptivity and intrauterine adhesive disease //Seminars in reproductive medicine. – Thieme Medical Publishers, 2014. – Т. 32. – №. 05. – С. 392-401.
  114. Gleicher N., Weghofer A., Barad D. H. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve //Fertility and Sterility. – 2010. – Т. 94. – №. 7. – С. 2824-2827.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу